CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
CD47 is a cell surface protein in the immunoglobulin superfamily which is normally expressed at low levels in every healthy cell. It´s main physiologic function is to act as an inhibitor of phagocytosis; this occurs throughout interaction with SIRPa expressed on macrophages. Interaction between CD47...
Saved in:
| Main Authors: | Rodrigo Catalán, Mario Orozco-Morales, Norma Y. Hernández-Pedro, Alberto Guijosa, Ana L. Colín-González, Federico Ávila-Moreno, Oscar Arrieta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/9435030 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CD47/SIRPα axis: bridging innate and adaptive immunity
by: Sjoerd H van der Burg, et al.
Published: (2022-07-01) -
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
by: Hongfei Wang, et al.
Published: (2020-10-01) -
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
by: Bolan Yu, et al.
Published: (2022-02-01) -
Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway
by: Zubair Hussain, et al.
Published: (2025-06-01) -
Blocking the SIRPα-CD47 axis promotes macrophage phagocytosis of exosomes derived from visceral adipose tissue and improves inflammation and metabolism in mice
by: Yun-kai Lin, et al.
Published: (2025-02-01)